Galectin Therapeutics Inc Income Statement

Income Statement Dec2011 Dec2012 Dec2013 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.01M-0.34M-0.09M-0.09M-0.49M-1.03M-2.79M-5.54M
Operating items
Research & Development 3.55M4.53M5.69M11.72M6.47M7.47M17.98M23.82M31.74M32.13M36.57M
Selling, General & Administrative 6.86M5.37M6.42M4.53M7.13M5.97M5.47M6.36M6.62M5.94M5.86M
Operating Expenses 10.41M9.90M12.10M16.25M13.60M13.44M23.44M30.18M38.35M38.07M42.43M
Operating Income -10.41M-9.90M-12.10M-16.25M-13.60M-13.44M-23.44M-30.18M-38.35M-38.07M-42.43M
EBIT -10.41M-9.90M-12.10M-16.25M-13.60M-13.44M-23.44M-30.18M-38.35M-38.07M-42.43M
Non-operating items
Interest & Investment Income 0.02M0.02M0.02M0.02M0.04M0.23M0.07M0.00M0.05M0.23M0.34M
Other Non Operating Income -0.52M0.20M0.14M0.56M3.62M0.59M
Non Operating Income -0.51M0.22M0.02M0.01M-0.30M0.14M-0.02M-0.35M-0.42M-2.99M-4.61M
Net income details
EBT -10.39M-9.88M-12.09M-16.23M-13.90M-13.29M-23.46M-30.66M-39.33M-40.63M-47.63M
Profit After Tax -10.91M-9.68M-12.09M-16.23M-13.90M-13.29M-23.46M-30.53M-38.78M-41.07M-47.05M
Income from Continuing Operations -10.39M-9.88M-12.09M-16.23M-13.90M-13.29M-23.46M-30.66M-39.33M-40.63M-47.63M
Consolidated Net Income -10.39M-9.88M-12.09M-16.23M-13.90M-13.29M-23.46M-30.66M-39.33M-40.63M-47.63M
Income towards Parent Company -10.39M-9.88M-12.09M-16.23M-13.90M-13.29M-23.46M-30.66M-39.33M-40.63M-47.63M
Preferred Dividend Payments 1.57M0.98M0.87M1.23M1.15M0.26M0.14M0.17M0.10M0.12M0.15M
Net Income towards Common Stockholders -12.71M-10.88M-21.95M-17.47M-15.05M-20.18M-23.60M-30.70M-38.87M-44.80M-47.20M
Additional items
EPS (Basic) -1.06-0.72-1.30-0.49-0.38-0.39-0.41-0.52-0.65-0.74-0.76
EPS (Weighted Average and Diluted) -0.41-0.52-0.65-0.74-0.76
Shares Outstanding (Weighted Average) 12.84M15.97M18.31M35.64M41.14M56.89M57.08M59.34M59.43M61.85M62.76M
EBITDA -10.41M-9.90M-12.10M-16.25M-13.60M-13.44M-23.44M-30.18M-38.35M-38.07M-42.43M
Interest Expenses 0.01M0.34M0.09M0.09M0.49M1.03M2.79M5.54M